2 results match your criteria: "Slovak Medical University and National Cancer Institute[Affiliation]"
Detection, significance and potential utility of circulating tumor cells in clinical practice in breast cancer (Review).
Oncol Lett
January 2025
Department of Surgical Oncology, Faculty of Medicine, Slovak Medical University and National Cancer Institute, 833 10 Bratislava, Slovak Republic.
Article Synopsis
- Advances in breast cancer care have improved survival, but the disease still significantly impacts women's health.
- Circulating tumor cells (CTCs) are valuable biomarkers for monitoring breast cancer, providing insights into treatment response and helping with risk assessment.
- Ongoing research and trials are exploring how to effectively use CTC data in clinical practice to enhance therapy outcomes for breast cancer patients.
Paclitaxel, Ifosfamide, and Cisplatin in Patients with Poor-prognosis Disseminated Nonseminomatous Germ Cell Tumors with Unfavorable Serum Tumor Marker Decline After First Cycle of Chemotherapy. The GCT-SK-003 Phase II Trial.
Eur Urol Open Sci
November 2021
2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, Slovak Republic.
Background: Germ cell tumors represent highly curable disease even in metastatic stage. However, poor-risk patients with an unfavorable serum tumor marker (STM) decline after the first cycle of chemotherapy represent a subgroup with dismal prognosis, with approximately 50% cure rate using bleomycin, etoposide, and cisplatin (BEP).
Objective: The aim of this study was to determine the efficacy and safety of paclitaxel, ifosfamide, and cisplatin (TIP) in this patient population.